formoterol 12 micrograms inhalation powder, hard capsule
laboratorios liconsa, s.a. - formoterol fumarate - inhalation powder, hard capsule - 12 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol
marbeta l kit- betamethasone sodium phosphate, betamethasone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidi
asclemed usa, inc. - betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - betamethasone 3 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.4, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection/bupivacaine hydrochloride and epinephrine injection is contraindicated
marbeta 25 kit- betamethasone sodium phosphate and betamethasone acetate, bupivacaine hydrochloride, povidine iodine kit
asclemed usa, inc. - betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - betamethasone 3 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.4, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection/bupivacaine hydrochloride and epinephrine injection is contraindicated
tobeta-xl metoprolol succinate 47.5 mg modifed release tablet blister pack
arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; sodium stearylfumarate; triethyl citrate; croscarmellose sodium; purified talc; macrogol 6000; silicified microcrystalline cellulose; silicon dioxide; methacrylic acid copolymer; povidone; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolol succinate190 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 190 mg - tablet, modified release - excipient ingredients: povidone; methacrylic acid copolymer; croscarmellose sodium; ethylcellulose; purified talc; sodium stearylfumarate; microcrystalline cellulose; macrogol 6000; triethyl citrate; silicified microcrystalline cellulose; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolol succinate 23.75 mg modified release tablet bottle pack
pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; sodium stearylfumarate; macrogol 6000; povidone; purified talc; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolo succinatel 47.5 mg modified release tablet bottle
pharmacor pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: triethyl citrate; sodium stearylfumarate; povidone; silicified microcrystalline cellulose; croscarmellose sodium; ethylcellulose; microcrystalline cellulose; purified talc; methacrylic acid copolymer; silicon dioxide; macrogol 6000; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolol succinate 95 mg modified release tablet bottle
pharmacor pty ltd - metoprolol succinate, quantity: 95 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; triethyl citrate; povidone; silicified microcrystalline cellulose; microcrystalline cellulose; silicon dioxide; ethylcellulose; purified talc; macrogol 6000; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolol succinate 23.75 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: purified talc; macrogol 6000; microcrystalline cellulose; povidone; silicon dioxide; triethyl citrate; sodium stearylfumarate; croscarmellose sodium; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.
tobeta-xl metoprolol succinate 95 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 95 mg - tablet, modified release - excipient ingredients: silicified microcrystalline cellulose; purified talc; macrogol 6000; methacrylic acid copolymer; microcrystalline cellulose; povidone; croscarmellose sodium; ethylcellulose; silicon dioxide; triethyl citrate; sodium stearylfumarate; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.